

Concurrent malaria and dengue fever in (sub-Saharan) Africa: a systematic review and meta-analysis

Tewelde T. Gebremariam,^{1,2*} Zeleke Mekonnen,³ Jonas B. Danquah,⁴

¹ Department of Microbiology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

² Department of Medical Microbiology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.

³ School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia.

⁴ Animal Research Institute, Animal Health Division Council for Scientific & Industrial Research, Accra, Ghana.

*Correspondence: ttesfayg@gmail.com

E-mail addresses:

TG: ttesfayg@gmail.com

ZM: zeleke.mekonnen@gmail.com

JD: jonydan4@gmail.com

ABSTRACT

Objectives To determine the prevalence of concurrent malaria and dengue fever, aetiologies, and the association between the two infections in Africa.

Methods We assessed evidence from previous studies in Africa that were available in MEDLINE and EMBASE databases between January 01, 2005, and March 30, 2022.

Results A total of 3942 studies were identified from the databases of which 30 studies from 13 African countries, including 25,241 febrile patients, were included in the meta-analysis. The result of the meta-analysis showed a 4.0% pooled prevalence of concurrent malaria and dengue fever in (sub-Saharan) Africa, and the highest rate was recorded in Central Africa (5.8%) followed by East Africa (4.7%) and West Africa (2.8%). Children <18 years old (57%) and females (52.8%) were more affected by the co-infection than adults and females, respectively. The dengue virus serotypes identified were DENV-2, DENV-3, DENV-1, and DENV-4 in descending order with a proportion of 39%, 31%, 27%, and 3%, respectively. Moreover, *Plasmodium falciparum* was the only specified malaria parasite in the co-infection among the included studies. Significantly higher odds of malaria infection were documented due to dengue fever when compared with malaria mono-infection. However, no significant odds of acute dengue co-infection were recorded due to malaria in contrast to dengue mono-infection.

Conclusion This study showed a high prevalence of concurrent malaria and dengue fever in Africa. Healthcare workers should bear in mind the possibility of dengue infection as differential diagnoses for acute febrile illness as well as the possibility of co-existent malaria and dengue in endemic areas. Also, high-quality multi-centre studies are required to verify the above conclusions.

Protocol registration number: [CRD42022311301](#).

Keywords Prevalence, Co-infection, Malaria, Dengue fever, Dengue virus, DENV, *Plasmodium falciparum*.

INTRODUCTION

Acute undifferentiated febrile illness (AUFI) is one of the most frequent reasons for healthcare seeking in Africa.¹ AUFI usually begins with non-specific symptoms such as the sudden onset of fever which fever progresses to prolonged duration, headache, chills, and myalgia which may later involve specific organs. It can range from mild and self-limiting illness to advancing, deadly disease.² Malaria and dengue fever are leading causes of AUFI.³

Africa carries the highest global malaria burden, with 2000 million cases (92%) in 2017 alone.⁴ Human malaria is mainly caused by four *Plasmodium* species, namely *P. falciparum*, *P. vivax*, *P. malariae*, and *P. ovale* with variable geographic distribution. *P. falciparum* accounts for nearly all malaria deaths in sub-Saharan Africa, which bears over 90% of the global malaria burden.⁵ Likewise, the prevalence of dengue in the region has dramatically increased over the past few decades although this specific infection is neither systematically investigated nor generally considered by clinicians.⁶ In 2013, about 16 million apparent and over 48 million inapparent dengue were estimated to have occurred, and most countries in the continent reported recurrent outbreaks.⁷ Similarly, dengue fever is caused by four genetically distinct dengue viruses (serotypes 1-4).⁸

Though malaria or dengue virus mono-infection can be severe, concomitant infections could be even more fatal.^{9, 10} The two mosquito-borne diseases have an overlapping epidemic pattern in Africa.¹¹ Due to their similar clinical presentation, possible concurrent malaria-dengue fever is often neglected¹² and generally misdiagnosed as malaria only.^{6, 13} Misdiagnosis is more probable during co-infection than mono-infection and this may result in slow identification of dengue fever outbreaks with potentially high morbidity and mortality.^{6, 14}

This review aimed to gather evidence to answer the question: how common is *Plasmodium* and dengue virus co-infection in Africa could be? The specific review objectives were (1) to determine the prevalence of concurrent malaria and acute dengue in Africa (by region and demographic characteristics), and (2) to describe the dengue virus serotypes in the concurrent infection.

METHODS

The protocol of the review was registered in the International Prospective Register of Systematic Reviews, PROSPERO ([CRD42022311301](https://doi.org/10.1111/1362-1324.1301)) and followed the Joanna Briggs Institute (JBI)¹⁵ and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)¹⁶ checklists (see online supplementary research checklists).

Inclusion and exclusion criteria

Case report, cross-sectional and case-control studies that reported concurrent malaria and dengue fever among uncomplicated febrile cases in African regions were included. According to the United Nations, Africa is divided into five regions: Northern Africa, Central or Middle Africa, Southern Africa, East Africa, and Western Africa.¹⁷ Similarly, the World Bank lists a total of 48 countries in the sub-Saharan African region.¹⁸

Malaria might be diagnosed by malaria rapid diagnostic tests or microscopy and/or polymerase chain reaction while dengue fever might be identified through antigen/antibody test and/or reverse transcriptase-polymerase chain reaction. Acute dengue or dengue fever was defined as positive for dengue IgM or NS1 antigen test or RT-PCR.

Articles of which full texts could not be obtained or were not available in English were excluded.

The primary outcome measure was the prevalence of concurrent malaria and dengue infection in Africa. The secondary outcomes were: (1) the proportion of males and females with concurrent malaria and acute dengue, and (2) the proportion of dengue virus serotypes in the co-infection. The literature screening and selection process is depicted in Figure 1.




Figure 1 Flowchart showing the identification and selection process of articles for inclusion in the review.

Databases and search strategy

The CoCoPop mnemonic (condition, context, and population)¹⁹ was used to formulate the review question and systematically search all relevant studies published between January 01, 2005, to March 30, 2022, from MEDLINE and EMBASE databases. The search strategy used was: **(exp Malaria, Falciparum/ or Malaria/ or ((*Plasmodium falciparum* or *Plasmodium infect** or malignant tertian or (malaria or marsh or remittent)) adj3 fever).ti,ab.) and (exp Dengue/ or exp Dengue Virus/ or ((dengue or Break?bone) adj3 fever).ti,ab.)**.

Study quality appraisal and data extraction

The Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI) tool²⁰ was used to screen each article and extract relevant data for the review. Two of the authors (TT, JD) independently screened each article at an abstract and full-text level. The discrepancy between the two reviewers was resolved through discussion. Articles endorsed in the full-text screening were subjected to JBI critical appraisal tool. Those with good quality scores were undergone data extraction. Data extraction included the first author's last name, publication year, country/region of study, sample size, number of concurrent malaria and dengue infections, demographic characteristics (age, gender) of patients with concurrent infections, and dengue serotypes in the concurrent infections. The JBI criteria were used to score the quality of each study. Studies with a score greater than or equal to four were seen as good quality to be included in the meta-analysis.

Statistical analysis

The meta-analysis was performed using Jamovi software (version 2.2.5)²¹, OpenMeta-analyst²², and the JBI SUMARI tool.²⁰ The random-effect model (DerSimonian-Laid) and the effect size model measures of raw proportion/Freeman-Tukey double arcsine transformed proportion were

used to determine the prevalence/proportion estimates. The heterogeneity of included studies was measured using Tau, Tau², I² statistic, and Cochran's Q-test. Forest plot was used to visually assess the prevalence and odds ratio with their 95% confidence intervals (CIs). Publication bias was evaluated using Egger's regression test and Rank Correlation Test. P-value <0.05 was considered statistically significant.

Patient and public involvement

This study was done without patient or public involvement.

RESULTS

Literature retrieval and article characteristics

A total of 3942 records were identified during literature retrieval from the databases. A total of 30 studies from (sub-Saharan) Africa involving 25,241 febrile patients were included in this meta-analysis²³⁻⁵³ (Figure 1, Table 1). The quality score of the included studies ranged from 4 to 7 on a maximum scale of quality scores of 8 for case reports, 9 for cross-sectional studies, and 11 for case-control studies using the JBI criteria (Table 1).

Table 1. Basic Characteristics and quality score of included studies.

Studies	Country	Study design	Sample size	Quality score according to JBI criteria
Stoler 2015	Ghana	Cross-sectional	218	5
Ahmed 2021	Sudan	Cross-sectional	76	4
Charrel 2005	Guinea	Case report	1	6
Sow 2016	Senegal	Cross-sectional	13845	6
Abdulaziz 2020	Nigeria	Cross-sectional	440	4
Ayorinde 2016	Nigeria	Cross-sectional	60	4
Baba 2013	Nigeria	Cross-sectional	310	4
Dariano 2017	Sierra Leone	Cross-sectional	1260	4
Miri 2021	Nigeria	Cross-sectional	94	4
Oyero 2014	Nigeria	Cross-sectional	188	4
Onyedibe 2018	Nigeria	Cross-sectional	529	5
Nassar 2019	Nigeria	Cross-sectional	170	5

Kolawole 2017	Nigeria	Cross-sectional	176	5
Vu 2016	Kenya	Cross-sectional	579	5
Ali 2020	Tanzania	Cross-sectional	149	4
Shah 2020	Kenya	Cross-sectional	862	4
Marks 2021	Burkina Faso, Madagascar, Sudan	Cross-sectional	615	6
Akelew 2022	Ethiopia	Cross-sectional	200	4
Boillat-Blanco 2018	Tanzania	Case-control	431	6
Chipwaza 2014	Tanzania	Cross-sectional	364	5
Obonyo 2018	Kenya	Cross-sectional	1332	6
Tchetgna 2021	Cameroon	Cross-sectional	320	5
Galani 2020	Cameroon	Cross-sectional	174	4
Mouiche 2020	Cameroon	Cross-sectional	629	5
Nkenfou 2021	Cameroon	Cross-sectional	349	4
Proesmans 2019	DRC	Cross-sectional	342	4
Tchuandom 2018	Cameroon	Cross-sectional	961	7
Yousseu 2018	Cameroon	Cross-sectional	114	4
Monamele 2018	Cameroon	Cross-sectional	33	4
Otu 2019	Nigeria	Cross-sectional	420	4

JBI, Joanna Briggs Institute; DRC, Democratic Republic of Congo.

Concurrent falciparum malaria and dengue fever

The random-effect (DerSimonian-Laird) model estimator and raw proportion and/or Freeman-Tukey double arcsine transformed proportion were used in the meta-analysis. The prevalence of malaria and dengue co-infection in (sub-Saharan) Africa per 1000 febrile cases was 40 (95% CI, 32 – 48, SE = 0.004) with significant heterogeneity (Tau= 0.018, Tau² = 0.00, I² = 95.52%, and Q = 625.28, p < 0.001) (Figure 2).




Figure 2 Forest plot delineating prevalence of malaria and acute dengue co-infection in (sub-Saharan) Africa.

The prevalence significantly varies across the three African regions ($\chi^2 = 537.13$, $p < 0.00001$) and ranges from 28.5 per 1000 febrile cases (95% CI, 18 – 39, SE = 0.0052) in West Africa (Figure 3), 47 (95% CI, 19 – 75, SE = .0142) in East Africa (Figure 4) to 58 (95% CI, 30 – 86, SE = 0.0143) in Central Africa (Figure 5) (Table 2). A case report²³ was excluded from the prevalence estimation.




Figure 3 Forest plot showing the prevalence of malaria and acute dengue co-infection in West Africa.




Figure 4 Prevalence of malaria and dengue co-infection in East Africa.




Figure 5 Forest plot depicting prevalence of concurrent malaria and acute dengue in Central Africa.

Table 2 Meta-analysis of concurrent malaria and acute dengue prevalence among febrile patients in three African regions.

Region	No. of studies	No. of cases	Heterogeneity					Model	Meta-analysis	
			P	T	T ²	Q	I ² (%)		E (95% CI) [×1000]	P
Central Africa	8	157	<.001	0.037	0.00	140.95	95.0	Random	57.7 (30, 86)	<.001
East Africa	8	248	<.001	0.039	0.00	214.42	96.7	Random	47 (19, 75)	<.001
West Africa	12	145	<.001	0.015	0.00	159.55	93.1	Random	28.5 (18, 39)	<.001

T, tau; Q, cochrane Q-test, p, p-value.

Twenty-two studies examined the association between acute dengue virus infection with malaria. The peto's odds ratio⁵⁴ was used to pool the odds ratio of individual studies. In our meta-analysis (Figure 6), cross-sectional studies in Cameroon^{38, 53}, and Kenya³⁰ revealed significantly lower odds of co-infection in contrast with the absence of acute dengue infections (OR: 0.60; 95% CI, 0.42 – 0.87). Cross-sectional studies in Nigeria^{24, 26, 28, 33, 40, 41, 43}, Tanzania²⁵, Sierra Leone³¹, Democratic Republic of Congo (DRC)⁴², Cameroon³⁹, Sudan^{48, 50}, and Senegal²⁹ indicated no significant odds of co-infection in comparison with acute dengue negatives (OR = 1.07; 95% CI = 0.58, 1.94). Studies in Ethiopia⁵², Nigeria³⁷, Tanzania⁴⁴, Cameroon⁵¹, and Kenya⁴⁷, on the other hand, indicated significantly higher odds of concurrent infection to acute

dengue negatives (OR = 4.56; 95% CI = 3.29, 6.33). There was no indication of a potential outlier (studentized residuals $>\pm 3.0654$) and overlay influence (cook's distance) among the studies. Above all, the summary estimate derived from 22 studies showed significantly higher odds of malaria infection among patients in the absence of acute dengue than acute dengue virus co-infection (OR = 1.51; 95% CI = 1.31, 1.75) with significant heterogeneity ($I^2 = 89$; $p < 0.001$). The 95% prediction interval for the true outcomes (log peto's odds ratio) was -1.41 to 2.46.




Figure 6 Forest plot: the difference in the prevalence of malaria due to acute dengue virus infection and malaria mono-infection.

Similarly, the odds of acute dengue virus infection were also compared with the presence and absence of malaria infection (Figure 7). Cross-sectional studies in Kenya^{30, 47} and

Cameroon^{38, 53} reported significantly low odds of acute dengue in the presence of malaria than in its absence (OR = 0.57, 95% CI, 0.40 – 0.82). Similar studies Nigeria^{26, 28, 33, 40, 41, 43}, Tanzania²⁵, Sierra Leone³¹, DRC⁴², Cameroon³⁹, Sudan^{48, 50}, and Senegal²⁹; however, showed no notable odds of acute dengue infection in the presence of malaria when compared to the absence of malaria (OR = 1.07, 95% CI, 0.58 – 1.94). On the contrary, cross-sectional studies in Ethiopia⁵², Nigeria^{24, 37}, Tanzania⁴⁴, and Cameroon⁵¹ indicated higher odds of acute dengue infection in the presence of malaria than in its absence (OR = 6.98, 95% CI, 2.89 – 16.85). The overall estimate based on 22 studies showed no significant odds of acute dengue co-infection in contrast to malaria mono-infection (OR = 1.00, 95% CI, 0.87 – 1.16) with significant heterogeneity ($I^2 = 86$, $P < 0.0001$). The 95% prediction interval for the true outcomes (log peto's odds ratio) was -1.45 – 2.127.




Figure 7 Forest plot showing the difference in the prevalence of acute dengue co-infection due to malaria and acute dengue mono-infection.

The gender distribution among malaria and acute dengue virus co-infection showed that the proportion of females was 52.8% (95% CI, 44.1 – 61.5, SE = 0.044) without evidence of heterogeneity ($I^2 = 0\%$, $p = 0.62$), while the proportion of males was 47.2% (95% CI, 38.5 – 55.9, SE = 0.044) with no evidence of heterogeneity ($I^2 = 0\%$, $p = 0.62$) (Table 3). Furthermore, the proportion age category of the coinfection was 57.0% (40.9-73.1, SE = 0.082) among children <18 years old and 40.9% (95% CI, 24.5 – 57.0, SE = 0.082) in adults with significant heterogeneity ($p < 0.001$).

Table 3 Meta-analysis of demographic characteristics of patients with concurrent malaria and dengue virus infection in (sub-Saharan) Africa.

Heterogeneity	Meta-analysis
---------------	---------------

Demography	No. of studies	No. of patients	<i>P</i>	T	T ²	Q	I ² (%)	Model	E (95% CI) [×100]	<i>P</i>
Gender										
Female	7	62	0.62	0.00	0	6.29	0	Random	52.8 (44.1, 61.5)	<.001
Male	7	54	0.62	0.00	0	6.29	0	Random	47.2 (38.5, 55.9)	<.001
Age										
Children	8	158	<.001	0.26	0.07	641.78	98.13	Random	57 (40.9, 73.1)	<.001
Adults	7	49	<.001	0.26	0.07	637.02	98.12	Random	40.9 (24.8, 57.0)	<.001

I², a measure of heterogeneity; p, significant level. Abbreviations: CI, confidence interval, E, estimate; children, <18 years old; adults, ≥18 years old; T, tau; Q, Cochran's Q-test.

The meta-analysis on the proportion of aetiologies of concomitant malaria and acute dengue is shown in Table 4. All the four dengue virus serotypes were identified, where DENV-2, DENV-3, DENV-1, and DENV-4 were documented in descending order with a proportion of 39.5% (95% CI, 16.8-62.2, SE = 0.116), 31.6% (95% CI, 16.0 – 47.2, SE = 0.080), 27.3% (95% CI, 14.6 – 40.1, SE = 0.065), and 3.7% (95% CI, 1.0 – 6.3, SE = 0.014), respectively. The aetiology of malaria among the co-infection was specified in 50.7% (95% CI, 29.6 – 71.9, SE = 0.108) of the patients, and all were due to *P. falciparum*.

Table 4 Meta-analysis of the proportion of aetiologies of concomitant malaria and acute dengue in (sub-Saharan) Africa.

	No. of studies	No. of patients	Heterogeneity					Model	Meta-analysis	
			<i>P</i>	T	T ²	Q	I ² (%)		E (95% CI) [×100]	<i>P</i>
DENV serotypes										
DENV-2	7	97	<.001	.39	.15	331.3	96.4	Random	39.5 (16.8, 62.2)	<.001
DENV-3	7	36	<.001	.25	.06	216.2	94.5	Random	31.6 (16.0, 47.2)	<.001
DENV-1	6	33	<.001	.20	.04	118.1	89.8	Random	27.3 (14.6, 40.1)	<.001
DENV-4	3	7	0.81	.00	0	7.7	0	Random	3.7 (1.0, 6.3)	.01
<i>Plasmodium</i> species										
Pf	16	305	<.001	.57	.33	15549.5	99.8	Random	50.7 (29.6, 71.9)	<.001
NS	14	251	<.001	.58	.33	15549.5	99.8	Random	49.3 (28.1, 70.4)	<.001

I², a measure of heterogeneity; p, significant level. Abbreviations: CI, confidence interval; E, estimate; Pf, *Plasmodium*

falciparum; NS, not specified; T, tau; Q, cochrans' Q-test.

Publication bias

The publication bias of included studies was evaluated using the funnel plot asymmetry tests: the Egger's regression test and rank correlation test based on the Freeman-Tukey double arcsine transformed proportion effect size model measures for prevalence/proportion estimates and log odds ratio peto's method for the difference in the prevalence rates. Both tests showed nonsignificant publication bias ($p > 0.05$) among the studies included in all the analyses.

DISCUSSION

The first report of malaria and dengue virus co-infection in Africa was documented in 2005.²³ Our meta-analysis included 25,241 febrile patients from 30 studies conducted in 13 African countries (Ghana, Sudan, Senegal, Nigeria, Guinea, Sierra Leone, Kenya, Tanzania, Ethiopia, Cameroon, DRC, Burkina Faso, and Madagascar) for over around 17 years. As far as we know, this is the first description and analysis of the prevalence, demographic characteristics, and dengue virus serotype profiles of concurrent malaria and dengue infection in (sub-Saharan) Africa.

Based on our analysis, the pooled prevalence of concurrent malaria and dengue was 4.0%, and the highest rate was recorded in Central Africa (5.8%), followed by East Africa (4.7%) and West Africa (2.8%). This result is lower than the finding of a study⁵⁵ on a meta-analysis of severe malaria and dengue co-infection which estimated a prevalence of 32%. The variation could be due to the differences in the study population, model estimator employed,

and/or geography of the primary studies included, where our analysis was focused on studies from Africa while the other study included studies from all over the globe. Besides, uncomplicated febrile cases were included in our analysis, unlike above the study which estimated severe malaria prevalence among the co-infection.

In our study, women and children were more affected groups by the concomitant infection than males and adults, respectively. Women and children are more susceptible to mosquito-borne illnesses because they are exposed to mosquito bites for longer periods during dangerous hours⁵⁶. Moreover, malaria⁵⁷ and dengue⁵⁸ mainly affect children due to underdeveloped specific immunity to infection.⁵⁷

In our analysis, the most prevalent dengue virus serotypes present in the concurrent infection were serotypes 2 and 3. The DENV-2 serotype is divided into six genotypes: Asian I, Asian II, American, Asian/American, Cosmopolitan, and Sylvatic.⁵⁹ The cosmopolitan genotype of DENV-2 is the most widely distributed dengue virus worldwide. The DENV-3 serotype of genotype III is found in Africa.⁶⁰ Furthermore, *Plasmodium falciparum* was the only malaria parasite specified in the coinfection among the included studies. It is known that nearly all malaria cases in (sub-Saharan) Africa are caused by *P. falciparum*.⁵

Our study also reported significantly higher odds of malaria infection among patients with malaria mono-infection than acute dengue virus co-infection. This could be due to the inter-species cross-protection of dengue virus infection against malaria.¹¹ Our finding does not corroborate the reports of Kotepui et al. 2019⁵⁵ and Kotepui et al. 2020⁶¹. Kotepui et al. 2019 showed significantly lower odds of co-infection while Kotepui et al. 2020 reported no notable difference in co-infection due to acute dengue compared to malaria mono-infection. Our study further elucidated no significant odds of acute dengue virus co-infection infection due to malaria

than acute dengue virus mono-infection. Our report is in disagreement with the findings of Kotepui et al. 2020⁶¹ which indicated higher odds of acute dengue due to malaria co-infection in contrast to dengue virus mono-infection. The discordant findings could be attributed to the variation in model estimator/effect size model measures and/or quality/geography of included studies.

Strengths and limitations

The strengths of this study are its large sample size, the good quality score of studies included in the analysis, and no evidence of publication bias among the included studies. Some of the study limitations include: (1) Our search was restricted to those published in English only, so language bias could have flawed our findings, (2) The analysis was dependent on single-centred studies, which may not accurately reflect the true prevalence of the concurrent infection on the African continent, (3) The sample sizes for six studies^{23, 28, 33, 35, 45, 48} were relatively small, so the sampling error could lead to substantial bias in the meta-analysis, (4) Our analysis showed significant heterogeneity among the studies due to too many outcomes, and (5) Subgroup analysis was not performed which could affect the accuracy of the results presented.

CONCLUSION

In general, our study found a high prevalence of concurrent malaria and dengue fever among febrile patients in (sub-Saharan) Africa with significant variation across regions. Women and children were more affected population groups by the coinfection than men and adults, respectively. *P. falciparum* and dengue virus serotype 2 and 3 were the predominant aetiologies of this coinfection in the region. Healthcare workers should bear in mind the possibility of

dengue infection as one of the differential diagnoses for acute febrile illness as well as the possibility of co-existent malaria and dengue in endemic areas. Our study also showed significantly higher odds of malaria infection were documented due to acute dengue co-infection in contrast to malaria mono-infection. Furthermore, no notable odds of acute dengue infection were reported due to malaria co-infection as compared to dengue mono-infection. Besides, high-quality multi-centre prospective studies are required to verify the above conclusions and to gain more insights into malaria and dengue virus co-infection in the continent.

Acknowledgement Not applicable.

Contributorship TG designed the study, wrote the statistical analysis plan, monitored the review process, interpreted the data, cleaned and analysed the data, and wrote the draft manuscript. TG and JD assessed studies for inclusion. ZM and AH reviewed and commented the draft paper. All authors have approved the final version. TG is the guarantor and takes responsibility for the content of this article.

Funding No funding has been received to conduct this study.

Competing interests The authors have no conflict of interest to declare; no support was obtained from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Patient consent Consent was not required when conducting a systematic review.

Ethics approval This study did not require ethical approval as the data used have been published previously, and hence are already in the public domain.

Data sharing Extracted data will be available upon request to the corresponding author.

REFERENCES

1. Escadafal C, Geis S, Siqueira AM, Agnandji ST, Shimelis T, Tadesse BT, et al. Bacterial versus non-bacterial infections: a methodology to support use-case-driven product development of diagnostics. *BMJ Glob Health*. 2020;5(10):e003141.
2. Bhargava A RR, Chatterjee B, Bottieau E. Assessment and initial management of acute undifferentiated fever in tropical and subtropical regions. *BMJ*. 2018;363:k4766.
3. Prasad N, Murdoch DR, Reyburn H, Crump JA. Etiology of severe febrile illness in low- and middle-income countries: a systematic review. *PLoS One*. 2015;10(6):e0127962.
4. World Health Organization. World Malaria Report. Geneva, Switzerland: WHO; 2018 [Available from: https://www.afro.who.int/sites/default/files/halth_topics_infographics/WHO_infographics_malaria.pdf].
5. Snow RW, Omumbo JA. Disease and Mortality in Sub-Saharan Africa. 2nd edition. Chapter 14 Malaria. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006 [Available from: <https://www.ncbi.nlm.nih.gov/books/NBK2286/>].
6. Gainor EM, Harris E, LaBeaud AD. Uncovering the burden of dengue in Africa: considerations on magnitude, misdiagnosis, and ancestry. *Viruses*. 2022;14(2):233.
7. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504-7.
8. World Health Organization. Dengue and severe dengue.: WHO; 2022 [Available from: <https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue>].

9. Epelboin L, Hanf M, Dussart P, Ouar-Epelboin S, Djossou F, Nacher M, et al. Is dengue and malaria co-infection more severe than single infections? A retrospective matched-pair study in French Guiana. *Malar J.* 2012;11:142.
10. Ward DI. A case of fatal *Plasmodium falciparum* malaria complicated by acute dengue fever in East Timor. *Am J Trop Med Hyg.* 2006;75(1):182-5.
11. Bygbjerg IC, Simonsen L, Schiøler KL. Elimination of *falciparum* malaria and emergence of severe dengue: an independent or interdependent phenomenon? *Front Microbiol.* 2018;9:1120.
12. Wiwanitkit V. Concurrent malaria and dengue infection: a brief summary and comment. *Asian Pac J Trop Biomed.* 2011;1(4):326-7.
13. Abdul-Ghani R, Mahdy MAK, Alkubati S, Al-Mikhlaflay AA, Alhariri A, Das M, et al. Malaria and dengue in Hodeidah city, Yemen: High proportion of febrile outpatients with dengue or malaria, but low proportion co-infected. *PLoS One.* 2021;16(6):e0253556.
14. Charrel RN, Brouqui P, Foucault C, de Lamballerie X. Concurrent dengue and malaria. *Emerg Infect Dis.* 2005;11(7):1153-4.
15. JBI. Critical appraisal tools. 2020 [Available from: <https://jbi.global/critical-appraisal-tools>].
16. PRISMA. PRISMA 2020 Checklist. 2020 [Available from: <http://www.prisma-statement.org/>].
17. Pitt. African Studies and African Country Resources: University of Pittsbergh; 2022 [Available from: <https://pitt.libguides.com/>].
18. World B. All countries of Sub-Saharan Africa. : World Bank; 2022 [Available from: <https://openknowledge.worldbank.org/pages/focus-sub-saharan-africa>].
19. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc.* 2015;13(3):147-53.
20. SUMARI J. End to end support for developing systematic reviews. 2022 [Available from: <https://sumari.jbi.global/>].
21. Project TJ. Jamovi (version 2.2), computer software. 2021 [Available from: <https://www.jamovi.org>].

22. Wallace BC, Dahabre IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: R as a computational back-end. *J Stat Softw.* 2012;49(5):1-15.
23. Charrel RN, Brouqui P, Foucault C, de Lamballerie X. Concurrent dengue and malaria. *Emerg Infect Dis.* 2005;11(7):1153-4.
24. Baba M, Logue CH, Oderinde B, Abdulmaleek H, Williams J, Lewis J, et al. Evidence of arbovirus co-infection in suspected febrile malaria and typhoid patients in Nigeria. *J Infect Dev Ctries.* 2013;7(1):51-9.
25. Chipwaza B, Mugasa JP, Selemani M, Amuri M, Mosha F, Ngatunga SD, et al. Dengue and chikungunya fever among viral diseases in outpatient febrile children in Kilosa District Hospital, Tanzania. *PLoS Negl Trop Dis.* 2014;8(11).
26. Oyero OG, Ayukekbong JA. High dengue NS1 antigenemia in febrile patients in Ibadan, Nigeria. *Virus Res.* 2014;191:59-61.
27. Stoler J, Delimini RK, Bonney JHK, Awandare GA. Evidence of recent dengue exposure among malaria parasite-positive children in three urban centers in Ghana. *Am J Trop Med Hyg.* 2014;91(5 SUPPL. 1):427.
28. Ayorinde AF, Oyeyiga AM, Nosegbe NO, Folarin OA. A survey of malaria and some arboviral infections among suspected febrile patients visiting a health centre in Simawa, Ogun State, Nigeria. *Journal of Infection and Public Health.* 2016;9(1):52-9.
29. Sow A, Loucoubar C, Diallo D, Ndiaye Y, Senghor CS, Dia AT, et al. Concurrent malaria and arbovirus infections in Kedougou, southeastern Senegal. *Malar J.* 2016;15(1):47.
30. Vu DM, Ripp K, Mutai N, Ndenga BA, Heath C, LaBeaud AD. *Plasmodium falciparum* co-infection modulates dengue disease severity. *Am J Trop Med Hyg.* 2016;95(5 Supplement 1):32.
31. Dariano DF, Taitt CR, Jacobsen KH, Bangura U, Bockarie AS, Bockarie MJ, et al. Surveillance of vector-borne infections (chikungunya, dengue, and malaria) in Bo, Sierra Leone, 2012-2013. *Am J Trop Med Hyg.* 2017;97(4):1151-4.
32. Kolawole OM, Seriki AA, Irekeola AA, Bello KE, Adeyemi OO. Dengue virus and malaria concurrent infection among febrile subjects within Ilorin metropolis, Nigeria. *J Med Virol.* 2017;89(8):1347-53.

33. Miri MF, Mawak JD, Chukwu CO, Chuwang NJ, Acheng SY, Ezekiel T. Detection of IgM and IgG dengue antibodies in febrile patients suspected of malaria attending health centre in Jos, Nigeria *Annals of Medical Laboratory Science*. 2017;1(1):27-35.
34. Boillat-Blanco N, Klaassen B, Mbarack Z, Samaka J, Mlaganile T, Masimba J, et al. Dengue fever in Dar es Salaam, Tanzania: clinical features and outcome in populations of black and non-black racial category. *BMC Infect Dis*. 2018;18(1):644.
35. Monamele GC, Demanou M. First documented evidence of dengue and malaria co-infection in children attending two health centers in yaounde, cameroon. *Pan Afr Med J*. 2018;29:227.
36. Obonyo M, Fidhow A, Ofula V. Investigation of laboratory confirmed dengue outbreak in north-eastern Kenya, 2011. *PLoS One*. 2018;13(6):e0198556.
37. Onyedibe K, Dawurung J, Iroezindu M, Shehu N, Okolo M, Shobowale E, et al. A cross sectional study of dengue virus infection in febrile patients presumptively diagnosed of malaria in Maiduguri and Jos plateau, Nigeria. *Malawi medical journal : the journal of Medical Association of Malawi*. 2018;30(4):276-82.
38. Tchandom SB, Tchouangueu TF, Antonio-Nkondjio C, Lissom A, Djang JON, Atabonkeng EP, et al. Seroprevalence of dengue virus among children presenting with febrile illness in some public health facilities in Cameroon. *Pan Afr Med J*. 2018;31:177.
39. Yousseu FBS, Nemg FBS, Ngouanet SA, Mekanda FMO, Demanou M. Detection and serotyping of dengue viruses in febrile patients consulting at the New-Bell District Hospital in Douala, Cameroon. *PLoS One*. 2018;13(10):e0204143.
40. Nassar SA, Olayiwola JO, Bakarey AS, Enyhowero SO. Investigations of dengue virus and *Plasmodium falciparum* among febrile patients receiving care at a tertiary health facility in Osogbo, south-west Nigeria. *Nigerian Journal of Parasitology*. 2019;40(1):18-24.
41. Otu AA, Udoh UA, Ita OI, Hicks JP, Egbe WO, Walley J. A cross-sectional survey on the seroprevalence of dengue fever in febrile patients attending health facilities in Cross River State, Nigeria. *PLoS One*. 2019;14(4):e0215143.

42. Proesmans S, Katshongo F, Milambu J, Fungula B, Mavoko HM, Ahuka-Mundeke S, et al. Dengue and chikungunya among outpatients with acute undifferentiated fever in Kinshasa, Democratic Republic of Congo: A cross-sectional study. *PLoS Negl Trop Dis*. 2019;13(9):e0007047.
43. Abdulaziz MM, Ibrahim A, Ado M, Ameh C, Umeokonkwo C, Sufyan MB, et al. Prevalence and factors associated with dengue fever among febrile patients attending secondary health facilities in Kano metropolis, Nigeria. *African J Clin Exp Microbiol*. 2020;21(4):340-8.
44. Ali MA, James OC, Mohamed AA, Joachim A, Mubi M, Omodior O. Etiologic Agents of Fever of Unknown Origin Among Patients Attending Mnazi Mmoja Hospital, Zanzibar. *J Community Health*. 2020;45(5):1073-80.
45. Ihahi JW, Oyugi E, Owiny M, Ogutu J, Serech H. Investigation of outbreak of malaria and other febrile illnesses in a remote Semi-Arid County, Kenya, 2019. *Am J Trop Med Hyg*. 2020;103(5 SUPPL):69.
46. Mouiche MMM, Ntumvi NF, Maptue VT, Tamoufe U, Albert B, Ngum Ndze V, et al. Evidence of Low-Level Dengue Virus Circulation in the South Region of Cameroon in 2018. *Vector-Borne and Zoonotic Diseases*. 2020;20(4):314-7.
47. Shah MM, Ndenga BA, Mutuku FM, Vu DM, Grossi-Soyster EN, Okuta V, et al. High dengue burden and circulation of 4 virus serotypes among children with undifferentiated fever, Kenya, 2014-2017. *Emerg Infect Dis*. 2020;26(11):2638-50.
48. Ahmed A, Eldigail M, Elduma A, Breima T, Dietrich I, Ali Y, et al. First report of epidemic dengue fever and malaria co-infections among internally displaced persons in humanitarian camps of North Darfur, Sudan. *Int J Infect Dis*. 2021;108:513-6.
49. Galani BRT, Mapouokam DW, Simo FBN, Mohamadou H, Chuisseu PDD, Njintang NY, et al. Investigation of dengue-malaria coinfection among febrile patients consulting at Ngaoundere Regional Hospital, Cameroon. *J Med Virol*. 2021;93(6):3350-61.
50. Marks F, Liu J, Soura AB, Gasmelseed N, Operario DJ, Grundy B, et al. Pathogens that cause acute febrile illness among children and adolescents in Burkina Faso, Madagascar, and Sudan. *Clin Infect Dis* 2021;73(8):1338-45.

51. Nkenfou CN, Fainguem N, Dongmo-Nguefack F, Yatchou LG, Kameni JJK, Elong EL, et al. Enhanced passive surveillance dengue infection among febrile children: Prevalence, co-infections and associated factors in Cameroon. *PLoS Negl Trop Dis*. 2021;15(4):e0009316.
52. Akelew Y, Pareyn M, Lemma M, Negash M, Bewket G, Derbew A, et al. Aetiologies of acute undifferentiated febrile illness at the emergency ward of the University of Gondar Hospital, Ethiopia. *Trop Med Int Health*. 2022;27(3):271-9.
53. Tchegnna HDS, Yousseu FS, Kamgang B, Tedjou A, McCall PJ, Wondji CS. Concurrent circulation of dengue serotype 1, 2 and 3 among acute febrile patients in Cameroon. *Int J Infect Dis*. 2022;116(Supplement):S125.
54. Brockhaus AC, Bender R, Skipka G. The Peto odds ratio viewed as a new effect measure. *Stat Med*. 2014;33(28):4861-74.
55. Kotepui M, Kotepui KU. Prevalence and laboratory analysis of malaria and dengue co-infection: a systematic review and meta-analysis. *BMC Public Health*. 2019;19(1):1148.
56. Quaresima V, Agbenyega T, Oppong B, Awunyo JADA, Adomah PA, Enty E, et al. Are malaria risk factors based on gender? A mixed-methods survey in an urban setting in Ghana. *Trop Med Infect Dis*. 2021;6(3).
57. Schumacher RF, Spinelli E. Malaria in children. *Mediterr J Hematol Infect Dis*. 2012;4(1):e2012073.
58. Tantawichien T. Dengue fever and dengue haemorrhagic fever in adolescents and adults. *Paediatr Int Child Health*. 2012;32 Suppl 1(s1):22-7.
59. Waman VP, Kolekar P, Ramtirthkar MR, Kale MM, Kulkarni-Kale U. Analysis of genotype diversity and evolution of Dengue virus serotype 2 using complete genomes. *PeerJ*. 2016;4:e2326.
60. Dorji T, Yoon IK, Holmes EC, Wangchuk S, Tobgay T, Nisalak A, et al. Diversity and origin of dengue virus serotypes 1, 2, and 3, Bhutan. *Emerg Infect Dis*. 2009;15(10):1630-2.
61. Kotepui M, Kotepui KU, Milanez GJ, Masangkay FR. Prevalence of and risk factors for severe malaria caused by Plasmodium and dengue virus co-infection: a systematic review and meta-analysis. *Infect Dis Poverty*. 2020;9(1):134.